NFL Biosciences
NFL Biosciences
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Biopharmaceutical company developing innovative botanical drugs for addiction treatment.
About
NFL Biosciences develops botanical drugs to treat addictions, focusing on tobacco, alcohol, and cannabis. Their pipeline includes innovative drug candidates like NFL-101 and NFL-102 for smoking cessation, and NFL-301 for excessive alcohol consumption, aiming to license these to pharmaceutical laboratories. The company leverages scientific expertise in botanical medicines and conducts preclinical and clinical studies.
Key facts
At-a-glance profile data
- Website
- nflbiosciences.com
- Headquarters
- Castelnau-le-Lez, France
- Founded
- 2001
- Total funding
- $16M (Bond Financing)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Post-money | Lead investors |
|---|---|---|---|---|
| 15 Apr 2026 | Bond Financing | $3M | - | - |
| 11 Mar 2026 | Loan | $500K | - | - |
| 22 May 2025 | Series A | $3M | - | - |
| 11 Mar 2024 | Debt Financing | $500K | - | Bpifrance |
| 31 Jan 2023 | Series A | $3M | - | - |
| 5 Jul 2021 | Public | $5M | $22M | - |
Tech stack
Detected on nflbiosciences.com, last scanned 21 Sept 2026. Run your own scan
- Compliance
- GDPR
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
Add first review
Frequently asked
How much funding has NFL Biosciences raised?
NFL Biosciences has raised a total of $16M in funding. The most recent round on record is Bond Financing.